Fig. 1From: Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancerCT results showing the metastatic lesions in the liver, lung and kidney before (a), four (b), eight (c), and twelve cycles (d) after cetuximab and FOLFIRI rechallenge, and two cycles (e) after cetuximab and capecitabine maintenance therapy. Arrows indicate the lesionsBack to article page